Breaking Insights| September 16 2022 Highlights from Recent Cancer Literature Author & Article Information Online ISSN: 1538-7445 Print ISSN: 0008-5472 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Res (2022) 82 (18): 3189–3190. https://doi.org/10.1158/0008-5472.CAN-82-18-BI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 16 2022 Citation Highlights from Recent Cancer Literature. Cancer Res 15 September 2022; 82 (18): 3189–3190. https://doi.org/10.1158/0008-5472.CAN-82-18-BI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Although BRCA1/2 alterations have been reported to predict platinum sensitivity, BRCA1 alterations have not consistently correlated with platinum sensitivity in clinical trials. Menghi and colleagues have now identified an explanation for these discordant results. They found that in contrast to BRCA1/2 mutations, BRCA1 promoter methylation (BRCA1meth) was not correlated with response to platinum agents in triple-negative breast and ovarian cancer patients. In vivo studies revealed that BRCA1meth is lost during chemotherapy treatment, leading to BRCA1 reactivation and acquired platinum resistance. Expert Commentary: This study suggests that the reversibility of BRCA1meth may explain the inconsistent platinum efficacy observed in BRCA1-deficient tumors. Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, et al. Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. Science Translational Medicine 2022;14:eabn1926. doi: 10.1126/scitranslmed.abn1926. Promoter methylation of the... You do not currently have access to this content.